ClinicalTrials.gg
CompletedNCT01232283ESTEEM 2Updated Mar 15, 2022Results posted

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

A Phase 3 interventional study of Apremilast and Placebo in Plaque Psoriasis, sponsored by Amgen. Completed at 46 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-15.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
6th of 44
413 · median 103
Started
2010
with 5 others
Phase 3
18 of 44
none open now
Registered
9th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 6th largest by enrollment, is one of 6 that started in 2010, is one of 18 in phase 3, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study is to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study will test efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, ≥ 18 years of age at the time of signing the document
  2. Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening

    a. Have moderate to severe plaque psoriasis at Screening and Baseline

  3. Must meet all laboratory criteria
  4. Females of (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use 2 forms of as described by the Study Doctor while on study medication and for at least 28 days after taking the last dose of study medication
  5. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex condom or any nonlatex condom NOT made out of natural [animal] membrane [eg, polyurethane]) while on study medication and for a least 28 days after the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  1. Other than psoriasis, history of any (as determined by the Investigator) or other major uncontrolled disease.
  2. Pregnant or breast feeding
  3. History of allergy to any component of the study drug
  4. surface antigen positive at Screening
  5. Anti- antibody positive at Screening
  6. Active tuberculosis (TB) or a history of incompletely treated TB
  7. Clinically significant abnormality on 12-Lead at Screening
  8. Clinically significant abnormal chest x-ray
  9. History of positive (HIV), or have congenital or acquired immunodeficiency
  10. Active substance abuse or a history of substance abuse within 6 months prior to Screening
  11. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening
  12. or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years)
  13. Psoriasis flare or rebound within 4 weeks prior to Screening
  14. Evidence of skin conditions that would interfere with clinical assessments
  15. Topical therapy within 2 weeks of randomization
  16. Systemic therapy for psoriasis within 4 weeks prior to randomization
  17. Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA)
  18. Adalimumab, etanercept, infliximab, or certolizumab pegol within 12 weeks prior to randomization
  19. Alefacept, briakinumab, or ustekinumab within 24 weeks prior to randomization
  20. Use of any drug within 4 weeks prior to randomization
  21. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources
  22. Prior treatment with apremilast
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
413 participants (actual)

Study arms

  • Experimental
    Apremilast

    Participants were initially randomized 2:1 and received apremilast 30 mg twice a day (BID). Participants maintained dosing through Week 32. At Week 32, responders, those with a Psoriasis Area Severity Index response -≥75 (PASI-75) and partial responders (≥PASI-50) were re-randomized 1:1 to apremilast 30 mg BID or matching placebo (treatment withdrawal). Participants could resume apremilast 30 mg BID at the time of loss of 50% of improvement in PASI score response which was observed at Week 32 compared to baseline), and no later than Week 52. At Week 52, the non-responders (\<PASI-50) had the option of adding topical therapies and/or phototherapy to their treatment regimen. Those re-randomized to apremilast 30 mg BID continued dosing through Week 52. At Week 52, participants continued treatment with apremilast 30 mg BID.

    Drug: Apremilast · Drug: Placebo · Other: Topical or Phototherapy Therapy

  • Placebo comparator
    Placebo

    Participants will be initially randomized to placebo, identically matching during Weeks 0-16. At Week 16, Placebo participants will be switched to receive apremilast 30 mg BID. All participants will maintain Apremilast dosing through Week 32. At Week 32, participants originally randomized to placebo at baseline (Week 0) and are considered non-responders i( \< PASI-50) will have the option of adding topical therapies and/or phototherapy to their Apremilast treatment regimen. At Week 52, all participants will continue treatment with apremilast 30 mg BID. Participants will be followed and evaluated for safety and efficacy for up to an additional 4 years (years 2 through 5).

    Drug: Apremilast · Drug: Placebo · Other: Topical or Phototherapy Therapy

Interventions

  • Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks

    Also known as: CC-10004, Otezla

  • DrugPlacebo

    Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.

  • OtherTopical or Phototherapy Therapy

    Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at week 16. The improvement in PASI score was used as a measure of efficacy. The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction From Baseline

    The sPGA was a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the Investigator must have factored in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign was averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score.

    Time frame: Baseline to Week 16

  2. Percent Change From Baseline in the Affected Body Surface Area (BSA) at Week 16

    BSA was a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline (Visit 2 Week 0) was determined at each visit of the study, which is calculated as 100\*(visit BSA - baseline BSA) / baseline BSA (%).

    Time frame: Baseline and Week 16

  3. Percent Change From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 16

    Psoriasis Area Severity Index (PASI) scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. The PASI score was set to missing if any severity score or degree of involvement is missing.

    Time frame: Baseline and Week 16

  4. Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score (PASI-50) at Week 16 From Baseline

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing.

    Time frame: Baseline and Week 16

  5. Change From Baseline in Pruritus Visual Analog Scale (VAS) Score at Week 16

    The Pruritus Visual Analog Scores (VAS) were used to measure the amount of itching and discomfort a participant experiences. Participant's Assessment of Pruritus (Itch) asked: On average, how much itch have you had because of your condition in the past week? All VAS values range from 0 to 100. Higher scores correspond to more severe symptom or disease. Change from baseline was calculated for the VAS scale, where change = visit value - baseline value.

    Time frame: Baseline and Week 16

  6. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

    DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score was derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

    Time frame: Baseline and Week 16

  7. Change From Baseline in the Mental Component Summary (MSC) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16

    The SF-36 was a 36-item general health instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Baseline to Week 16

  8. Percentage of Participants Who Achieved Both a 75% Improvement (Response) in the PASI and sPGA Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction at Week 16 From Baseline

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. See Outcome measure #1 for further description. sPGA is a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. See Outcome Measure #2 for further description.

    Time frame: Baseline to Week 16

  9. Time to Loss of Effect (Loss of 50% Improvement in PASI Score Obtained at Week 32 Compared to Baseline) During the Randomized Treatment Withdrawal Phase

    Time to loss was the time between the re-randomization date and the date of the first assessment with loss of 50% PASI improvement (event), or the time between the re-randomization date and the date of the last PASI assessment in the randomized withdrawal phase prior to addition of topical/phototherapy or other effective psoriasis therapies, or resumption of apremilast 30 mg BID, or discontinuation, or Week 52 if no loss (censored), whichever was earlier

    Time frame: Weeks 32 to Week 52

  10. Number of Participants With Treatment Emergent Adverse Events (TEAEs) in the Placebo Controlled Phase

    An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

    Time frame: Baseline to Week 16

  11. Number of Participants With Psoriasis Flare or Rebound in the Placebo Controlled Phase

    Psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention, or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. Note categories below. \[1\] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis) started on or after the first dose date and on or before the last dose date within the phase. \[2\] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis, Rebound psoriasis) started after the last dose date for participants who discontinued within the phase. \[3\] PASI \>= 125% of baseline score at any visit after the last dose date for participants who discontinued within the phase and were not included in \[1\] and/or \[2\].

    Time frame: Week 0 to Week 16

  12. Number of Participants With TEAEs During the Apremilast-Exposure Period Through Week 260

    The Apremilast-exposure Period started on the date of the first dose of apremilast (Week 0 for participants originally randomized to apremilast or Week 16 for participants originally randomized to placebo) to the last dose of apremilast. Adverse events that started after 28 days of initiating placebo and before resuming apremilast treatment in the Randomized Treatment Withdrawal Phase (Weeks 32 to 52) were excluded in the Apremilast-exposure phase. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

    Time frame: Week 0 to Week 260; The mean duration of exposure was 100.66 weeks.

  13. Number of Participants With Psoriasis Flare or Rebound in the Apremilast-Exposure Period

    Psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention, or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. Note categories below. \[1\] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis) started on or after the first dose date and on or before the last dose date within the phase. \[2\] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis, Rebound psoriasis) started after the last dose date for participants who discontinued within the phase. \[3\] PASI \>= 125% of baseline score at any visit after the last dose date for participants who discontinued within the phase and were not included in \[1\] and/or \[2\].

    Time frame: Week 0 to Week 260

07

Results

Posted Nov 5, 2014

Participant flow

The study was conducted at 46 study centers in 9 countries.

Placebo Controlled Phase (Weeks 0-16)
Participant flow — Placebo Controlled Phase (Weeks 0-16)
MilestoneApremilastPlaceboApremilast-ApremilastPlacebo-ApremilastAPR-APR-Re-randomized to PBOAPR-APR Re-randomized to APRAPR-APR-APR + Optional Topicals/PhototherapyPBO-APR-APR + Optional Topicals/PhototherapyApremilast (Long-Term Extension Phase)Placebo-Apremilast (Long-term Extension)
Started27513800000000
Received apremilast27213600000000
Completed23911200000000
Not completed362600000000
Withdrew: Adverse event12800000000
Withdrew: Lack of efficacy3200000000
Withdrew: Noncompliance with study drug1000000000
Withdrew: Withdrawal by subject9700000000
Withdrew: Lost to follow-up6600000000
Withdrew: Protocol violation3200000000
Withdrew: Other2100000000
Maintenance Phase (Weeks16-32)
Participant flow — Maintenance Phase (Weeks16-32)
MilestoneApremilastPlaceboApremilast-ApremilastPlacebo-ApremilastAPR-APR-Re-randomized to PBOAPR-APR Re-randomized to APRAPR-APR-APR + Optional Topicals/PhototherapyPBO-APR-APR + Optional Topicals/PhototherapyApremilast (Long-Term Extension Phase)Placebo-Apremilast (Long-term Extension)
Started00234108000000
Completed00194100000000
Not completed00408000000
Withdrew: Adverse event0082000000
Withdrew: Lack of efficacy00193000000
Withdrew: Non-compliance with study drug0010000000
Withdrew: Withdrawal by subject0071000000
Withdrew: Lost to follow-up0032000000
Withdrew: Other0020000000
Randomized Withdrawal Phase(Weeks 32-52)
Participant flow — Randomized Withdrawal Phase(Weeks 32-52)
MilestoneApremilastPlaceboApremilast-ApremilastPlacebo-ApremilastAPR-APR-Re-randomized to PBOAPR-APR Re-randomized to APRAPR-APR-APR + Optional Topicals/PhototherapyPBO-APR-APR + Optional Topicals/PhototherapyApremilast (Long-Term Extension Phase)Placebo-Apremilast (Long-term Extension)
Started00006261589600
Treated with apr+ topicals/phototherapy000000281700
Completed00005056418400
Not completed0000125171200
Withdrew: Adverse event0000210100
Withdrew: Lack of efficacy00004013500
Withdrew: Withdrawal by subject0000333400
Withdrew: Death0000100000
Withdrew: Lost to follow-up0000201100
Withdrew: Protocol violation0000000100
Withdrew: Other0000010000
Long-Term Extension Phase (Weeks 52-260)
Participant flow — Long-Term Extension Phase (Weeks 52-260)
MilestoneApremilastPlaceboApremilast-ApremilastPlacebo-ApremilastAPR-APR-Re-randomized to PBOAPR-APR Re-randomized to APRAPR-APR-APR + Optional Topicals/PhototherapyPBO-APR-APR + Optional Topicals/PhototherapyApremilast (Long-Term Extension Phase)Placebo-Apremilast (Long-term Extension)
Started0000000013780
Completed000000002919
Not completed0000000010861
Withdrew: Adverse event00000000116
Withdrew: Lack of efficacy000000004630
Withdrew: Non-compliance0000000032
Withdrew: Withdrawal by subject000000003014
Withdrew: Lost to follow-up0000000096
Withdrew: Death0000000010
Withdrew: Protocol violation0000000010
Withdrew: Miscellaneous0000000073

Outcome measures

PrimaryPercentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at week 16. The improvement in PASI score was used as a measure of efficacy. The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline
percentage of participantsApremilastPlacebo
Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline28.85.8
Statistical analysis
  • Apremilast vs Placebo · Chi-squared · p = <0.0001 · Risk difference (rd): 23.0 · 95% CI 16.3 to 29.6
SecondaryPercentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction From Baseline

The sPGA was a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the Investigator must have factored in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign was averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction From Baseline
percentage of participantsApremilastPlacebo
Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction From Baseline20.44.4
Statistical analysis
  • Apremilast vs Placebo · Chi-squared · p = <0.0001 · Risk difference (rd): 16.1 · 95% CI 10.2 to 21.9
SecondaryPercent Change From Baseline in the Affected Body Surface Area (BSA) at Week 16

BSA was a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline (Visit 2 Week 0) was determined at each visit of the study, which is calculated as 100\*(visit BSA - baseline BSA) / baseline BSA (%).

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Affected Body Surface Area (BSA) at Week 16
percent changeApremilastPlacebo
Percent Change From Baseline in the Affected Body Surface Area (BSA) at Week 16-48.40 ± 2.636-6.25 ± 3.710
Statistical analysis
  • Apremilast vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: -42.15 · 95% CI -51.11 to -33.20The model included treatment group as a factor and the baseline value as a covariate. The estimation and p-value were adjusted by the covariate.
SecondaryPercent Change From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 16

Psoriasis Area Severity Index (PASI) scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. The PASI score was set to missing if any severity score or degree of involvement is missing.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 16
percent changeApremilastPlacebo
Percent Change From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 16-50.8 ± 2.23-16.0 ± 3.15
Statistical analysis
  • Apremilast · ANCOVA · p = <0.0001 · Ls mean difference: -34.8 · 95% CI -42.4 to -27.2The model included treatment group as a factor and the baseline value as a covariate. The estimation and p-value were adjusted by the covariate.
SecondaryPercentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score (PASI-50) at Week 16 From Baseline

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing.

Time frame:
Baseline and Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score (PASI-50) at Week 16 From Baseline
Percentage of ParticipantsApremilastPlacebo
Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score (PASI-50) at Week 16 From Baseline55.519.7
Statistical analysis
  • Apremilast vs Placebo · Chi-squared · p = < 0.0001 · Risk difference (rd): 35.8 · 95% CI 26.9 to 44.7
SecondaryChange From Baseline in Pruritus Visual Analog Scale (VAS) Score at Week 16

The Pruritus Visual Analog Scores (VAS) were used to measure the amount of itching and discomfort a participant experiences. Participant's Assessment of Pruritus (Itch) asked: On average, how much itch have you had because of your condition in the past week? All VAS values range from 0 to 100. Higher scores correspond to more severe symptom or disease. Change from baseline was calculated for the VAS scale, where change = visit value - baseline value.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pruritus Visual Analog Scale (VAS) Score at Week 16
units on a scaleApremilastPlacebo
Change From Baseline in Pruritus Visual Analog Scale (VAS) Score at Week 16-33.5 ± 2.08-12.2 ± 2.95
Statistical analysis
  • Apremilast vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -21.3 · 95% CI -28.4 to -14.2The model included treatment group as a factor and the baseline value as a covariate. The estimation and p-value were adjusted by the covariate.
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score was derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
units on a scaleApremilastPlacebo
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16-6.7 ± 0.37-2.7 ± 0.53
Statistical analysis
  • Apremilast vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: -4.0 · 95% CI -5.3 to -2.8The model included treatment group as a factor and the baseline value as a covariate. The estimation and p-value were adjusted by the covariate.
SecondaryChange From Baseline in the Mental Component Summary (MSC) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16

The SF-36 was a 36-item general health instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Mental Component Summary (MSC) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16
units on a scaleApremilastPlacebo
Change From Baseline in the Mental Component Summary (MSC) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 162.60 ± 0.563-0.03 ± 0.804
Statistical analysis
  • Apremilast vs Placebo · ANCOVA · p = 0.0078 · Ls mean difference: 2.63 · 95% CI 0.69 to 4.56The model included treatment group as a factor and the baseline value as a covariate. The estimation and p-value were adjusted by the covariate.
SecondaryPercentage of Participants Who Achieved Both a 75% Improvement (Response) in the PASI and sPGA Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction at Week 16 From Baseline

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. See Outcome measure #1 for further description. sPGA is a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. See Outcome Measure #2 for further description.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Both a 75% Improvement (Response) in the PASI and sPGA Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction at Week 16 From Baseline
percentage of participantsApremilastPlacebo
Percentage of Participants Who Achieved Both a 75% Improvement (Response) in the PASI and sPGA Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction at Week 16 From Baseline18.64.4
Statistical analysis
  • Apremilast vs Placebo · Chi-squared · p = <0.0001 · Risk difference (rd): 14.2 · 95% CI 8.5 to 20.0
SecondaryTime to Loss of Effect (Loss of 50% Improvement in PASI Score Obtained at Week 32 Compared to Baseline) During the Randomized Treatment Withdrawal Phase

Time to loss was the time between the re-randomization date and the date of the first assessment with loss of 50% PASI improvement (event), or the time between the re-randomization date and the date of the last PASI assessment in the randomized withdrawal phase prior to addition of topical/phototherapy or other effective psoriasis therapies, or resumption of apremilast 30 mg BID, or discontinuation, or Week 52 if no loss (censored), whichever was earlier

Time frame:
Weeks 32 to Week 52
Reported as:
Median · Weeks
Time to Loss of Effect (Loss of 50% Improvement in PASI Score Obtained at Week 32 Compared to Baseline) During the Randomized Treatment Withdrawal Phase
WeeksAPR-APR Re-randomized to PBOAPR-APR-Re-randomized to APR
Time to Loss of Effect (Loss of 50% Improvement in PASI Score Obtained at Week 32 Compared to Baseline) During the Randomized Treatment Withdrawal Phase12.4 (8.3 to 20.1)21.9 (NA to NA)
Statistical analysis
  • APR-APR Re-randomized to PBO vs APR-APR-Re-randomized to APR · Log Rank · p = <0.0001 · Hazard ratio (hr): 7.700 · 95% CI 3.408 to 17.399
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) in the Placebo Controlled Phase

An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) in the Placebo Controlled Phase
participantsApremilastPlacebo
Any TEAE18582
Any drug related TEAE10629
Any Severe TEAE126
Any Serious TEAE53
Any TEAE leading to drug interruption164
Any TEAE leading to drug withdrawal157
SecondaryNumber of Participants With Psoriasis Flare or Rebound in the Placebo Controlled Phase

Psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention, or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. Note categories below. \[1\] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis) started on or after the first dose date and on or before the last dose date within the phase. \[2\] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis, Rebound psoriasis) started after the last dose date for participants who discontinued within the phase. \[3\] PASI \>= 125% of baseline score at any visit after the last dose date for participants who discontinued within the phase and were not included in \[1\] and/or \[2\].

Time frame:
Week 0 to Week 16
Reported as:
Number · participants
Number of Participants With Psoriasis Flare or Rebound in the Placebo Controlled Phase
participantsApremilastPlacebo
Participants with any psoriasis flare37
Participants with any psoriasis rebound10
PASI ≥ 125% of Baseline score after last dose12
SecondaryNumber of Participants With TEAEs During the Apremilast-Exposure Period Through Week 260

The Apremilast-exposure Period started on the date of the first dose of apremilast (Week 0 for participants originally randomized to apremilast or Week 16 for participants originally randomized to placebo) to the last dose of apremilast. Adverse events that started after 28 days of initiating placebo and before resuming apremilast treatment in the Randomized Treatment Withdrawal Phase (Weeks 32 to 52) were excluded in the Apremilast-exposure phase. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

Time frame:
Week 0 to Week 260; The mean duration of exposure was 100.66 weeks.
Reported as:
Number · participants
Number of Participants With TEAEs During the Apremilast-Exposure Period Through Week 260
participantsApremilast
Any TEAE316
Any Drug-Related TEAE165
Any Severe TEAE58
Any Serious TEAE44
Any Serious Drug-Related TEAE8
Any TEAE Leading to Drug Interruption56
Any TEAE Leading to Drug Withdrawal45
Any TEAE Leading to Death1
SecondaryNumber of Participants With Psoriasis Flare or Rebound in the Apremilast-Exposure Period

Psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention, or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. Note categories below. \[1\] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis) started on or after the first dose date and on or before the last dose date within the phase. \[2\] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis, Rebound psoriasis) started after the last dose date for participants who discontinued within the phase. \[3\] PASI \>= 125% of baseline score at any visit after the last dose date for participants who discontinued within the phase and were not included in \[1\] and/or \[2\].

Time frame:
Week 0 to Week 260
Reported as:
Number · participants
Number of Participants With Psoriasis Flare or Rebound in the Apremilast-Exposure Period
participantsApremilast
Participants with any psoriasis flare25
Participants with any psoriasis rebound11
PASI ≥ 125% of Baseline score after last dose12

Adverse events

Collected over AEs are reported at: 1. Weeks 0-16: PBO-controlled phase 2. Weeks 32-52 Randomized Withdrawal participants re-randomized to PBO at Week 32 3. Weeks 0-260 APR-exposure period for participants randomized or switched to APR at any time during the study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: Weeks 0-16 (PBO-Controlled Phase)—3/136 (2.2%)38/136 (27.9%)
Apremilast: Weeks 0-16 (PBO-Controlled Phase)—5/272 (1.8%)128/272 (47.1%)
APR-APR-PBO: Weeks 32-52 (Randomized Withdrawal Phase)—2/62 (3.2%)17/62 (27.4%)
Apremilast: Weeks 0-260 (APR- Exposure Period )—44/380 (11.6%)234/380 (61.6%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventPlacebo: Weeks 0-16 (PBO-Controlled Phase)Apremilast: Weeks 0-16 (PBO-Controlled Phase)APR-APR-PBO: Weeks 32-52 (Randomized Withdrawal Phase)Apremilast: Weeks 0-260 (APR- Exposure Period )
Haemorrhage intracranialNervous system disorders0/1360/2721/620/380
Parkinson's diseaseNervous system disorders0/1360/2721/621/380
PalpitationsCardiac disorders1/1360/2720/620/380
Non-cardiac chest painGeneral disorders1/1360/2720/621/380
SyncopeNervous system disorders1/1360/2720/621/380
AppendicitisInfections and infestations0/1360/2720/622/380
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1360/2720/622/380
PsoriasisSkin and subcutaneous tissue disorders0/1361/2720/622/380
Abdominal painGastrointestinal disorders0/1361/2720/621/380
DysphagiaGastrointestinal disorders0/1361/2720/621/380
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo: Weeks 0-16 (PBO-Controlled Phase)Apremilast: Weeks 0-16 (PBO-Controlled Phase)APR-APR-PBO: Weeks 32-52 (Randomized Withdrawal Phase)Apremilast: Weeks 0-260 (APR- Exposure Period )
NauseaGastrointestinal disorders9/13650/2722/6268/380
NasopharyngitisInfections and infestations6/13620/2725/6269/380
DiarrhoeaGastrointestinal disorders8/13643/2721/6262/380
Upper respiratory tract infectionInfections and infestations6/13613/2721/6253/380
Back painMusculoskeletal and connective tissue disorders2/1366/2722/6231/380
Tension headacheNervous system disorders2/13620/2720/6231/380
BronchitisInfections and infestations0/1364/2721/6229/380
HeadacheNervous system disorders1/13617/2720/6228/380
VomitingGastrointestinal disorders5/13614/2720/6227/380
ArthralgiaMusculoskeletal and connective tissue disorders2/1365/2722/6226/380

Baseline characteristics

The full analysis set (FAS) consisted of all participants who were randomized as specified in the protocol. Those who were randomized in error and did not receive any dose of Investigational product (IP) were excluded from FAS. Participants were included in the treatment group to which they were randomized APR 30 BID or placebo for the FAS.

Age, Continuous
Age, Continuous(years)ApremilastPlaceboTotal
Mean45.3 ± 13.0545.7 ± 13.3845.4 ± 13.15
Sex: Female, Male
Sex: Female, Male(Participants)ApremilastPlaceboTotal
Female9837135
Male176100276
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ApremilastPlaceboTotal
American Indian or Alaska Native112
Asian8614
Black or African American13215
Native Hawaiian or Other Pacific Islander101
White250128378
Other-not specified101
Duration of Plaque Psoriasis
Duration of Plaque Psoriasis(years)ApremilastPlaceboTotal
Mean17.94 ± 11.36718.68 ± 12.08818.19 ± 11.602
08

Study locations

46 sites
  • Arizona Skin and Laser Therapy Inst., Ltd.
    Phoenix, Arizona 85023, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Florida Academic Dermatology Center
    Miami, Florida 33136, United States
  • Advanced Medical Research
    Atlanta, Georgia 30342, United States
  • MedaPhase Inc.
    Newnan, Georgia 30263, United States
  • Northwestern University Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • PMG Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27104, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Radiant Research, Inc.
    Anderson, South Carolina 29560, United States
  • Austin Dermatology Associates
    Austin, Texas 78705, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Virginia Medical Research
    Norfolk, Virginia 23507, United States
  • Medizinische Universitat Wien, Universitatsklinik fur Dermatologie. Abteilung fur Immundermatologie
    Vienna, 1090, Austria
  • Northwest Dermatology and Laser Centre
    Calgary, Alberta T3G 0B4, Canada
  • Stratica Medical
    Edmonton, Alberta T5K 1X3, Canada
  • NewLab Clinical Research
    St. John's, Newfoundland and Labrador A1C 2H5, Canada
  • Skin Center for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Windsor Clinical Research Inc.
    Winsor, Ontario N8W 5L7, Canada
  • Q & T Research Sherbrooke Inc.
    Sherbrooke, Quebec J1H 4J6, Canada
  • Centre de Recherche Dermatologique du Quebec Metropolitain CRDQ
    Quebec, G1V 4X7, Canada
  • Bispebjerg Hospital
    Copenhagen, 2400, Denmark
  • Centre d'lnvestigation Clinique, Hopital Jean Minjoz
    Besancon, 25030, France
  • Hospital haut leveque
    Pessac, 33604, France
  • Larrey University Hospital
    Toulouse, 31000, France
  • Dr. med. Beatrice Gerlach
    Dresden, 01097, Germany
  • Universitatsklinikum Hamburg-Eppendorf / IVDP
    Hamburg, D-20246, Germany
  • Universitäts-Hautklinik Kiel
    Kiel, 24105, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • Hautarztpraxis Mahlow
    Mahlow, 15831, Germany
  • Universita degli Studi di Napoli Federico II
    Napoli, 80131, Italy
  • Istituto Dermatologico San Gallicano IRCCS Dermatologia Clinica
    Rome, 00144, Italy
  • A.O.U. Integrata di Verona Universitá degli Studi di Verona Sezione di Dermatologia e Venerologia
    Verona, 37126, Italy
  • Hospital Universitario Fundacion Alcorcon
    Alcorcón, 28922, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona (Barcelona), 8916, Spain
  • Hospital Abente y Lago
    La Coruna, 15006, Spain
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hopitaux Universitaires de Geneve-HUG
    Geneva, 1205, Switzerland
  • University of Zurich Hospital
    Zurich, 8091, Switzerland
09

References and documents

Publications

  • Reich K, Mrowietz U, Menter A, Griffiths CEM, Bagel J, Strober B, Nunez Gomez N, Shi R, Guerette B, Lebwohl M. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2409-2414. doi: 10.1111/jdv.17520. Epub 2021 Aug 23. PubMed 34255891 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Mar 2012, 15 months.

Results were first posted in Nov 2014, 2 years 7 months after primary completion. A results delay was requested in May 2013.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2010
First posted
Nov 2, 2010
StartActual
Nov 22, 2010
Primary completionActual
Mar 15, 2012
CompletionActual
Nov 30, 2016
Results delay requested
May 24, 2013
Results first posted
Nov 5, 2014
Last update
Mar 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01232283
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 2, 2010
Start date
Nov 22, 2010
Primary completion
Mar 15, 2012
Completion
Nov 30, 2016
Results posted
Nov 5, 2014
Last update
Mar 15, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion